HB 1228 expands access to experimental drugs, biological products, and devices for patients with advanced or serious illnesses by allowing them to try investigational treatments that have completed early safety testing but haven't yet received FDA approval. The bill defines "eligible patients" as those with progressive conditions like advanced illness or serious illness (involving extreme pain or permanent disability) who have exhausted standard treatment options. This creates a pathway for terminally ill or severely ill South Dakotans to seek access to experimental treatments outside of traditional clinical trials.
Senate Do Pass Failed, YEAS 6, NAYS 25. S.J. 469
Health and Human Services Do Pass Passed, YEAS 4, NAYS 3. S.J. 1
Health and Human Services Scheduled for hearing
Health and Human Services Do Pass Failed, YEAS 3, NAYS 2.
Health and Human Services Scheduled for hearing S.J. 1
First read in Senate and referred to Senate Health and Human Services S.J. 329
House of Representatives Do Pass Passed, YEAS 57, NAYS 13. H.J. 441
Health and Human Services Do Pass Passed, YEAS 9, NAYS 1.
Health and Human Services Scheduled for hearing
House of Representatives Referred to House Health and Human Services H.J. 156
First Reading House H.J. 139
Steven Haugaard
Prime sponsor · Rep.
R
Cosponsors
Do Pass
Health and Human Services — Do Pass
Health and Human Services — Do Pass
Do Pass
Health and Human Services — Do Pass